Studying at the University of Verona

Study Plan

A.A. 2024/2025 A.A. 2023/2024 A.A. 2022/2023 A.A. 2021/2022 A.A. 2020/2021 A.A. 2019/2020 A.A. 2018/2019 A.A. 2017/2018 A.A. 2016/2017 A.A. 2015/2016 A.A. 2014/2015 A.A. 2013/2014 A.A. 2012/2013 A.A. 2011/2012 A.A. 2010/2011 A.A. 2009/2010

This information is intended exclusively for students already enrolled in this course.
If you are a new student interested in enrolling, you can find information about the course of study on the course page:

Laurea magistrale a ciclo unico in Medicina e chirurgia - Enrollment from 2025/2026

The Study Plan includes all modules, teaching and learning activities that each student will need to undertake during their time at the University.
Please select your Study Plan based on your enrollment year.

1° Year

ModulesCreditsTAFSSD
7
A
BIO/16
6
A
BIO/13
15
A
BIO/10
10
A/B
FIS/07 ,MED/01
3
E
L-LIN/12
9
B
BIO/17
2
D
-

2° Year  activated in the A.Y. 2017/2018

ModulesCreditsTAFSSD
11
A
BIO/16
15
A/B
BIO/11 ,BIO/13 ,MED/03
9
B
MED/04
9
B
MED/07
7
B/F
- ,M-PSI/08 ,SPS/07
2
D
-

3° Year  activated in the A.Y. 2018/2019

ModulesCreditsTAFSSD
5
B
MED/08
10
A/C
BIO/09
12
A
BIO/09 ,M-PSI/01
5
B/C/F
- ,BIO/12
19
B
MED/04 ,MED/09
2
D
-

4° Year  activated in the A.Y. 2019/2020

ModulesCreditsTAFSSD
6
B
MED/28 ,MED/30 ,MED/31
9
B/C
BIO/14
10
B/F
- ,MED/09 ,MED/18
22
B/F
- ,MED/08 ,MED/12 ,MED/15 ,MED/16 ,MED/17 ,MED/35
17
B/F
- ,MED/08 ,MED/10 ,MED/11 ,MED/13 ,MED/14 ,MED/21 ,MED/22 ,MED/23
1
D
-

5° Year  activated in the A.Y. 2020/2021

ModulesCreditsTAFSSD
5
B
MED/08
6
B
MED/06 ,MED/18
9
B/F
- ,MED/40
6
B
MED/36
3
B
MED/33
11
B/C/F
- ,MED/09
7
B
MED/26 ,MED/27 ,MED/34
6
B
MED/25
12
B/F
- ,MED/20 ,MED/38 ,MED/39
9
B
MED/42 ,MED/43 ,MED/44
1
D
-

6° Year  activated in the A.Y. 2021/2022

ModulesCreditsTAFSSD
13
B/F
- ,MED/09 ,MED/45
9
B
MED/09 ,MED/18 ,MED/41
6
B/F
- ,MED/18 ,MED/24
6
F
NN
8
F
NN
5
F
NN
Prova finale
15
E
-
activated in the A.Y. 2017/2018
ModulesCreditsTAFSSD
11
A
BIO/16
15
A/B
BIO/11 ,BIO/13 ,MED/03
9
B
MED/04
9
B
MED/07
7
B/F
- ,M-PSI/08 ,SPS/07
2
D
-
activated in the A.Y. 2018/2019
ModulesCreditsTAFSSD
5
B
MED/08
10
A/C
BIO/09
12
A
BIO/09 ,M-PSI/01
5
B/C/F
- ,BIO/12
19
B
MED/04 ,MED/09
2
D
-
activated in the A.Y. 2019/2020
ModulesCreditsTAFSSD
6
B
MED/28 ,MED/30 ,MED/31
9
B/C
BIO/14
10
B/F
- ,MED/09 ,MED/18
22
B/F
- ,MED/08 ,MED/12 ,MED/15 ,MED/16 ,MED/17 ,MED/35
17
B/F
- ,MED/08 ,MED/10 ,MED/11 ,MED/13 ,MED/14 ,MED/21 ,MED/22 ,MED/23
1
D
-
activated in the A.Y. 2020/2021
ModulesCreditsTAFSSD
5
B
MED/08
6
B
MED/06 ,MED/18
9
B/F
- ,MED/40
6
B
MED/36
3
B
MED/33
11
B/C/F
- ,MED/09
7
B
MED/26 ,MED/27 ,MED/34
6
B
MED/25
12
B/F
- ,MED/20 ,MED/38 ,MED/39
9
B
MED/42 ,MED/43 ,MED/44
1
D
-

Legend | Type of training activity (TTA)

TAF (Type of Educational Activity) All courses and activities are classified into different types of educational activities, indicated by a letter.

A Basic activities
B Characterizing activities
C Related or complementary activities
D Activities to be chosen by the student
E Final examination
F Other training activities
S Placements in companies, public or private institutions and professional associations

Therapy with biologic agents in rheumatic diseases  (Corso Elettivo)  (2019/2020)

Teaching code

0903M

Teacher

Ombretta Viapiana

Coordinator

Ombretta Viapiana

Credits

1

Language

Italian

Scientific Disciplinary Sector (SSD)

MED/16 - RHEUMATOLOGY

Period

2° semestre 1°- 5° anno dal Feb 17, 2020 al May 29, 2020.

Lessons timetable Seminars 0

Learning outcomes

The endpoints of this course are:
to define the potential therapeutic targets of the most important articular inflammatory diseases;
to analyze ( in terms of efficacy, therapeutic indications and safety at short-long term) the biological drugs already in commerce or at II-III phase of reaserch.
to provide some indications regarding the management of the patients recieving biological drugs ( pre-treatment exams, clinical management, adverse events' management);
to discuss interactively with the students some specific clinical cases.

Program

The endpoints of this course are: to define the potential therapeutic targets of the most important articular inflammatory diseases; to analyze ( in terms of efficacy, therapeutic indications and safety at short-long term) the biological drugs already in commerce or at II-III phase of reaserch, to provide some indications regarding the management of the patients recieving biological drugs ( pre-treatment exams, clinical management, adverse events' management); to discuss interactively with the students some specific clinical cases.